SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: UPLOAD
Document Type: TEXT-EXTRACT
Date Filed: 2024-10-11
Accession Number: 0000000000-24-011566
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000000000024011566/filename2.txt

Chunk 0 of 1
Word Count: 257
Character Count: 1661

Document Content:

October 11, 2024

Jack Ross
Chief Executive Officer
Synergy CHC Corp.
865 Spring Street
Westbrook, ME 04092

Re: Synergy CHC Corp.
Amendment No. 6 to Registration Statement on Form S-1
Filed October 10, 2024
File No. 333-280556
Dear Jack Ross:

We have reviewed your amended registration statement and have the
following
comment.

Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our September
2024 letter.

Amendment No. 6 to Registration Statement on Form S-1
Certain Relationships and Related Party Transactions, page 72

1. We refer to your disclosure on page 72 concerning transactions conducted
pursuant to
your Sales and Marketing Consultant and Distribution Agreement with
Kenek
Brands. Please revise to clarify the reason(s) why the balance owing to
Kenek Brands
increased from $1,181,222 at June 30, 2024 to $2,760,159 at October 10,
October 11, 2024
Page 2

Please contact Tracie Mariner at 202-551-3744 or Vanessa Robertson at
3649 if you have questions regarding comments on the financial statements and
related
matters. Please contact Tamika Sheppard at 202-551-8346 or Joe McCann at
with any other questions.

Sincerely,

Division of Corporation
Finance
Office of Life Sciences
cc: Mike Bradshaw